Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802.
Bifunctional aromatic compounds are claimed to contain a β(2) agonist pharmacophore linked by a flexible lipophilic spacer incorporating a trans-4-aminocyclohexanol group to a muscarinic antagonist pharmacophore. The compounds display nanomolar affinity at both β(2) and M(3) receptors and a prolonged duration of action in animal models. This application is the first from Almirall claiming such compounds although it has recently disclosed that LAS-190792 is progressing toward clinical development.